MicroPort CardioFlow Medtech Management
Management criteria checks 2/4
MicroPort CardioFlow Medtech's CEO is Ruinian Zhang, appointed in Mar 2025, has a tenure of less than a year. directly owns 0.004% of the company’s shares, worth HK$102.59K. The average tenure of the management team and the board of directors is 5.1 years and 4.8 years respectively.
Key information
Ruinian Zhang
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.004% |
| Management average tenure | 5.1yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Why We're Not Concerned Yet About MicroPort CardioFlow Medtech Corporation's (HKG:2160) 26% Share Price Plunge
Nov 04
Does MicroPort CardioFlow Medtech (HKG:2160) Have A Healthy Balance Sheet?
Oct 06MicroPort CardioFlow Medtech Corporation's (HKG:2160) 50% Jump Shows Its Popularity With Investors
Jul 28Is There An Opportunity With MicroPort CardioFlow Medtech Corporation's (HKG:2160) 41% Undervaluation?
Jul 17MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable
Jun 12Take Care Before Jumping Onto MicroPort CardioFlow Medtech Corporation (HKG:2160) Even Though It's 37% Cheaper
Apr 08Revenues Tell The Story For MicroPort CardioFlow Medtech Corporation (HKG:2160) As Its Stock Soars 29%
Feb 10MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable
Sep 27After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar
Sep 27Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 43%?
Aug 07Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding
Jun 19MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans
May 29MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Apr 05We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
Feb 23An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued
Jan 18Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth
Oct 04Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%
May 31We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
May 23The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts
Apr 06MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans
Feb 08We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
Oct 18We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate
Jun 30Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts
Apr 04MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 03An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued
Jan 21Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?
Sep 05We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn
Jun 07Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)
May 03CEO
Ruinian Zhang (61 yo)
Mr. Ruinian Zhang is President, GM & Executive Director of MicroPort CardioFlow Medtech Corporation from March 27, 2025. Mr. Zhang has many years of experience in the fields of cardiovascular, general surg...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| VP & Executive Director | 5.2yrs | CN¥2.19m | 0.067% HK$ 1.8m | |
| Executive Director & First VP of Total Solutions | 3.5yrs | CN¥2.27m | 0.071% HK$ 2.0m | |
| President | less than a year | no data | 0.0037% HK$ 102.6k | |
| Joint Company Secretary | 5.1yrs | no data | no data | |
| Joint Company Secretary | 5.1yrs | no data | no data |
Experienced Management: 2160's management team is seasoned and experienced (5.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| VP & Executive Director | 5.2yrs | CN¥2.19m | 0.067% HK$ 1.8m | |
| Executive Director & First VP of Total Solutions | 3.5yrs | CN¥2.27m | 0.071% HK$ 2.0m | |
| President | less than a year | no data | 0.0037% HK$ 102.6k | |
| Independent Non-Executive Director | 4.8yrs | CN¥303.00k | no data | |
| Non-Executive Director | 6.3yrs | no data | no data | |
| Non-Executive Chairman of the Board | 5.2yrs | CN¥958.00k | 0.031% HK$ 846.9k | |
| Non-Executive Director | 6.3yrs | no data | no data | |
| Independent Non-Executive Director | 4.8yrs | CN¥303.00k | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
Experienced Board: 2160's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/20 11:50 |
| End of Day Share Price | 2025/11/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MicroPort CardioFlow Medtech Corporation is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harry He | CGS International |
| Bo Yu | China International Capital Corporation Limited |
| Yuan Gao | China International Capital Corporation Limited |